Nervgen Pharma NGEN
NASDAQ NGEN
$1.52 -0.02 (-1.29%)
As of: Oct 21, 2026 · 2:39 PM EDT

Nervgen Pharma (NGEN) Short term Debt (2024 - 2025)

Updated

Nervgen Pharma's Short term Debt came in at $6,001 for the quarter ended Dec 31, 2025, down 91.4% from $69,605 a year earlier.

Analysis

Nervgen Pharma (NGEN) Short term Debt (2024 - 2025) Analysis & Trends

As of Dec 31, 2025, Nervgen Pharma's Short term Debt was $5,990, down 91.6% from the prior year.

  • Going back by year, Short term Debt was $71,020 in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.90 Bn 1,105.48 Bn 19.71 Bn
2 Johnson & Johnson 617.06 Bn 535.59 Bn 17.26 Bn
3 AbbVie 501.38 Bn 474.49 Bn 12.70 Bn
4 Merck 367.41 Bn 321.79 Bn 12.21 Bn
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn
6 Astrazeneca 261.31 Bn 235.00 Bn 12.86 Bn
7 Amgen 236.29 Bn 191.69 Bn 7.24 Bn
8 Gilead Sciences 190.40 Bn 164.60 Bn 6.22 Bn
9 Pfizer 169.55 Bn 116.19 Bn 10.94 Bn
10 Nervgen Pharma 110.30 Mn 9.19 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 6,111.12
Dec 31, 2024 67,759.83
API Access

Nervgen Pharma Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=NGEN&period=max&api_key=YOUR_API_KEY